Correlation Between PD-L1 Expression And EGFR Mutation In Lung Adenocarcinoma

In recent years,lung cancer has been the leading cause of cancer-related deadth.The targeted therapy of non-small cell lung cancer(NSCLC)becomes the model of precision therapy.Epidermal growth factor receptor-tyrosine kinase inhibitor(EGFR-TKI),which epidermal growth factor receptor(EGFR)is the main target,greatly improves response rate(RR),objective response rate(ORR)and progression free survival(PFS)in NSCLC.However,acquiring resistance are inevitable,which limites the development of target medicine.Now,the effective prediction target may overcome resistance-drug.This can make the therapy of target medicine more individualized.With the advent of the era of immunotherapy of lung cancer,the research on PD-1/PD-L1 pathway has been gradually increased.The expression characteristics of PD-1 and PD-L1 are different in different malignant tumors,and they are often associated with various clinical pathological parameters,lymph node metastasis and prognosis of patients in lung cancer.However,PD-1/PD-L1 inhibitors,as single drug therapy or combined with other anti-tumor therapies,are controversial in non-small cell lung cancer.Also,high expression of programmed deadth ligand-1(PD-L1)is associated with EGFR sensitive mutation in NSCLC.The combined application of the two targeted drug will be the research focus.Here,This paper describes the correlation between pd-l1 and EGFR mutation in lung adenocarcinoma.